



The Winter Meeting of the Nutrition Society was held at the Royal College of Surgeons, London on 11–12 December 2013

Conference on ‘Diet, gut microbiology and human health’ Symposium 2: Changes in the microbiome in disease and lifecourse

Intestinal microbiota during early life – impact on health and disease

Lotta Nylund^{1,2*}, Reetta Satokari^{1,2}, Seppo Salminen¹ and Willem M. de Vos^{2,3,4}

¹Functional Foods Forum, University of Turku, Turku, Finland

²Department of Veterinary Biosciences, Division of Microbiology and Epidemiology, University of Helsinki, Helsinki, Finland

³Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands

⁴Immunobiology Research Program, Department of Bacteriology & Immunology, University of Helsinki, Helsinki, Finland

In the first years after birth, the intestinal microbiota develops rapidly both in diversity and complexity while being relatively stable in healthy adults. Different life-style-related factors as well as medical practices have an influence on the early-life intestinal colonisation. We address the impact of some of these factors on the consecutive microbiota development and later health. An overview is presented of the microbial colonisation steps and the role of the host in that process. Moreover, new early biomarkers are discussed with examples that include the association of microbiota and atopic diseases, the correlation of colic and early development and the impact of the use of antibiotics in early life. Our understanding of the development and function of the intestinal microbiota is constantly improving but the long-term influence of early-life microbiota on later life health deserves careful clinical studies.

**Microbiota development: Human milk oligosaccharides: Weaning: Biomarker bacteria:
Allergy and atopic diseases: Colic: Antibiotics**

Major colonisation of the intestinal microbiota starts at delivery when an infant comes into contact with microbes from the extrauterine environment. The microbial community co-evolves with its human host and after reaching the full complexity, outnumbers human cells by one or more orders of magnitude^(1,2). The collective genome of these microbes (also called microbiome) contributes significantly to our genetic coding capacity as they are found to contain over 3 million genes⁽³⁾. Unlike our own genome, the intestinal microbiome is not strictly vertically inherited. Moreover, this personalised ‘organ’ may be modified by a variety of foods, food components and pharmaceutical treatments targeting microbiota composition, stability and activity. While developing rapidly in diversity and complexity in the first years following birth, the intestinal microbiota becomes relatively stable in adulthood. A recent longitudinal

study showed that the subject-specificity of the adult intestinal microbiota was maintained for over 10 years⁽⁴⁾. This long-term stability provides further support for the cross-talk between the human host and microbiota⁽⁵⁾.

A series of changes in life style, such as improved hygienic conditions, reduced contact with companion or farm animals and a higher frequency of caesarean deliveries as well as expanded broad spectrum antibiotic use and dietary habits of both the infant and mother affect the intestinal colonisation process⁽⁶⁾ (Fig. 1). Many of the factors described earlier are typical for an urban life style and are likely to lead to decreased exposure to microbes from the natural environment. Such exposure is thought to be essential both for the development of balanced microbiota diversity and composition and the optimal maturation of immune system⁽⁶⁾, thus having lasting impact on later life health.

Abbreviations: CD, coeliac disease; HMO, human milk oligosaccharides; MAMP, microbe-associated molecular patterns; TLR, Toll-like receptors; Th, T helper.

*Corresponding author: L. Nylund, email lotta.nylund@utu.fi




Fig. 1. (colour online) Modern life style factors associated with the development of intestinal microbiota and later life health.

Prenatal exposure to microbes and microbial compounds

Traditionally the fetus has been thought to be microbiologically sterile before birth. The presence of microbes in the amniotic fluid and placenta has mainly been associated with preterm deliveries due to maternal intra-uterine infections and other pathological conditions⁽⁷⁻⁹⁾ and the presence of bacterial DNA in amniotic fluid has been associated with lower gestational age and with low mean birth weight^(9,10). However, recent studies utilising molecular methods have shown that DNA of non-pathogenic bacteria can be detected in placenta and amniotic fluid samples in normal conditions^(11,12). Hence, ingestion of amniotic fluid during pregnancy continuously exposes the fetus to bacteria and/or microbe-associated molecular patterns (MAMP). The exact mechanism(s) of bacterial entry into the intrauterine environment remains elusive. However, ascension from the vagina, by retrograde spread from abdominal cavity, haematogeneously through placenta and contamination during medical procedures (such as amniocentesis) have been suggested as potential routes⁽¹³⁾. Also MAMP can induce the immunostimulatory effects, for example via the stimulation of Toll-like receptors (TLR), without the need for microbial cells to enter the amniotic cavity. This is supported by the study by Rautava *et al.* where the presence of bacterial DNA, indicative for the presence of other MAMP too, in placenta and amniotic fluid was associated with the induction of expression profiles of TLR, especially TLR2 and TLR5 in fetal intestine⁽¹²⁾.

Furthermore, the expression of different TLR, including TLR9, has been shown to change during the

maturation of gut epithelial cells^(14,15). TLR9 recognises unmethylated CpG motifs in bacterial DNA and its signalling maintains the gut epithelial homeostasis by improving the barrier functions and by inducing tolerance towards other MAMP⁽¹⁶⁾. *In utero* the intestinal expression of TLR9 of mouse embryos decreases from days 14 to 18 and then increases again during the post-natal period⁽¹⁵⁾. Thus, it appears that a full-term newborn is programmed to receive TLR9 stimulation, which will improve the tolerance towards commensal bacteria. Consistently with this, necrotising enterocolitis in preterm infants has been associated with decreased TLR9 and increased TLR4 expression of the intestinal epithelium⁽¹⁵⁾. Remarkably, TLR9 activation via CpG-DNA supplementation significantly reduced necrotising enterocolitis severity⁽¹⁵⁾ suggesting that microbiota rich in CpG motifs but poor in TLR4 ligands, such as lipopolysaccharide-carrying Gram-negative bacteria could be optimal for the prevention or alleviation of necrotising enterocolitis. In this regard human breast milk, which supports the growth of Bifidobacteria, organisms with high-guanine-cytosine content genomes that are especially rich in CpG-motifs, appears to be a 'superfood' for the newborns. A number of strains of commercially produced lactobacilli have also been found to be rich in CpG-DNA⁽¹⁶⁾ and probiotic interventions have shown some promising results in the prevention and alleviation of necrotising enterocolitis⁽¹⁷⁾. In a mouse model, TLR9 signalling was indeed observed to be an essential mediator of anti-inflammatory effects of probiotics⁽¹⁸⁾. Furthermore, DNA of *Bifidobacterium* and *Lactobacillus* spp., both rich in CpG motifs, have been found in human placenta⁽¹¹⁾. Thus, it seems that

prenatal exposure to MAMP is an important step in programming the development of gut epithelium and immune system already *in utero*.

Early-life microbiota

Meconium is the very first faecal specimen produced by the infant after birth. It consists mainly of amniotic fluid but includes also mucus, intestinal epithelial cells and concentrate of metabolites such as bile acids and pancreatic secretions⁽¹⁹⁾. Several reports have described meconium microbiota composition providing further evidence for the suggestion that microbiological colonisation may begin already *in utero*^(20–23).

Bacteria belonging to four major bacterial phyla in the intestine, Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria, are already detectable in the meconium. The predominant cultured bacteria seem to be bacilli within the Firmicutes phylum such as enterococci and staphylococci, or certain Proteobacteria such as *Esherichia coli*, *Klebsiella* and *Enterobacter* spp.^(20–24). This is in agreement with the reports that these facultative anaerobes are present in faeces of healthy newborn infants^(25,26). In addition, *Enterococcus* spp. are commonly present, ~40 and 50% of infants colonised at day 3, respectively⁽²⁵⁾. Following the colonisation of facultative bacteria, anaerobic bacteria appear in the infant faeces within the first weeks of life, decreasing the abundance of facultative anaerobes and thus introducing a shift in microbiota community structure⁽²⁷⁾. It should be noted, however, that this shift may represent an outgrowth of specific groups of bacteria and does not preclude the fact that their colonisation might have already occurred at low level. Especially the abundance of Bifidobacteria increases rapidly from ~3–5–10% in meconium^(20,22,28) to 50–70% and even up to 90% in the faeces of breast-fed infants at ages 1 month and 3 months, respectively^(29–32). However, large inter-individual variations are characteristic for infant microbiota and the abundance of Bifidobacteria varies from 5 to 100% in breast-fed infants⁽³²⁾. Considering formula-fed infants, Bifidobacteria (determined by fluorescent *in situ* hybridisation) may form a minor part of the microbiota, constituting ~25% of the total microbiota⁽³²⁾. In addition to the individual variation, the Bifidobacterial abundance seems to vary greatly according to the geographic origin; infants from (northern) European countries harbour in general high numbers of Bifidobacteria^(30,32,33), whereas these bacteria are less predominant in Asian and American infants^(26,34,35). This observation can be mainly explained by demographic differences and by differences in the rate and duration of breast-feeding between the countries and potentially also the differences in use of antibiotics.

After the introduction of solid foods and weaning the relative abundance of Bifidobacteria decreases gradually being ~60% at 4 months, 25% at 6 months and 10% at 2 years^(27,36,37). Simultaneously, the relative abundance of lactobacilli decreases, whereas bacteria predominant in adult microbiota, such as Bacteroidetes and bacteria

belonging to the *Clostridium* clusters XIVa and IV increase^(32,35–37). However, the early-life microbiota composition is characterised by high inter-individual variation^(27,36,38). The bacterial abundances in healthy infant microbiota vary greatly in a subject-wise manner and fluctuate further in response to the changes in different life events such as antibiotic treatments and introduction of solid foods^(26,35) (Fig. 1). During and after weaning major changes occur in microbiota diversity and composition, this transitional phase being more pronounced in breast-fed than in formula-fed infants⁽³²⁾. The succession of *Bacteroides* spp. and bacteria belonging to the *Clostridium* clusters XIVa and IV proceeds rapidly while the relative proportion of Bifidobacteria decreases^(32,35).

Previously, it has been suggested that the microbiota diversity and composition stabilise and reach the level of adult microbiota within the first year or two^(26,39). However, recent studies have shown that microbiota maturation will continue longer^(36,37,40). Interestingly, the establishment of bacteria belonging to *Clostridium* cluster XIVa at a level similar to adults has been observed already in young children (age 1–4 years)⁽³⁷⁾, while other bacterial groups still remain at low-level abundance. This indicates that the microbiota development is a gradual process, where some bacterial groups may reach the degree of stabilisation earlier than others. However, considering the major physiological changes taking place in the human body within childhood and adolescence it may be argued that the development of the intestinal microbiota continues throughout this time period and is not finished until the human host reaches adulthood. The first studies on adolescent microbiota also point to this direction as they reported significant differences between the microbiota composition of adolescent children (age 11–18 years) and adults, the most striking difference being the almost 2-fold higher abundance of Bifidobacteria in adolescent subjects (9 v. 5.5% of total microbiota, respectively)⁽⁴⁰⁾. However, in order to comprehensively understand the microbiota development and stabilisation, more longitudinal studies analysing time-series samples from the same individuals over a long-time period are needed.

Effect of breast milk on microbiota composition

Human milk oligosaccharides (HMO) have an essential role in the promotion of the development of normal physiology of intestine and immune system in infants. Human milk contains a complex mixture of oligosaccharides, their exact composition varying according to different extrinsic and intrinsic factors. These factors include the genetic background of the mother, maternal health status, diet, secretor status and Lewis blood group type^(41–43). Oligosaccharide molecules participate in the maintenance of a healthy gut microbiota in three ways. (1) They block the colonisation of pathogenic bacteria by acting as receptor analogues and binding to the bacterial surface, thus preventing the pathogens from binding to their target oligosaccharides on the epithelial

cell surface⁽⁴⁴⁾. (2) They act as prebiotic substrates promoting the growth of beneficial bacteria, notably Bifidobacteria, concurrently preventing the adherence of potentially harmful bacteria via colonisation resistance⁽⁴¹⁾. (3) They have also been suggested to modulate intestinal epithelial cells, lymphocyte cytokine production and leucocyte rolling and adhesion (comprehensively reviewed by Bode⁽⁴¹⁾).

Human infants lack the extensive set of enzymes needed for the digestion of glycan residues of HMO. Thus, these molecules pass undigested to the lower part of the intestinal tract, where they can be consumed by the specific members of infant gut microbiota⁽⁴⁵⁾. Since a wide repertoire of enzymes are needed for the degradation and utilisation of the intricate structures of both HMO and plant polysaccharides, such processes most likely involve several different commensal bacteria acting synergistically. The two major bacterial genera described to have the capability for milk oligosaccharide utilisation are *Bifidobacterium* spp. and *Bacteroides* spp. Bifidobacteria, such as *Bifidobacterium longum* subsp. *infantis* and *Bifidobacterium bifidum*, typically abundant in infant microbiota, harbour a complex set of genes specifically related to HMO utilisation⁽⁴⁶⁾. The *B. longum* subsp. *infantis* genome harbours entire gene clusters controlling the expression of glycosidases, membrane-spanning transporters and other proteins dedicated to human milk oligosaccharide utilisation^(46,47). In contrast, *B. longum* subsp. *longum*, which is more abundant in adult microbiota, is unable to use diverse HMO, but has the capability to utilise short-chain oligosaccharides⁽⁴⁶⁾. However, HMO have reported to up-regulate the expression of several pathways in *B. longum* subsp. *Longum*, such as genes involved in carbohydrate degradation and cell adherence⁽⁴⁸⁾. Possibly, *B. longum* subsp. *longum* relies on cross-feeding with other bacteria, which first degrade complex polysaccharides to shorter units and thereby can also use HMO as a nutrient source.

Bacteroides spp. genomes harbour a specific gene cluster termed polysaccharide utilisation loci, enabling a wide range of saccharolytic ability^(45,49). For example, *Bacteroides thetaiotaomicron* can degrade more than a dozen different types of glycans⁽⁴⁵⁾, most likely also HMO. In addition, *in vitro* utilisation of HMO by *Bacteroides fragilis* and *Bacteroides vulgatus* has been reported⁽⁴⁵⁾. Consistently, *B. fragilis* and *B. vulgatus* are the predominant *Bacteroides* spp. found in breast-fed infants⁽⁵⁰⁾. The abundance of bacterial groups, which have restricted capacity to utilise different polysaccharide compounds, are likely to fluctuate more in response to the type of incoming carbohydrates, whereas bacteria with a wide glycan-degrading capability may have a competitive advantage in the gut. *Bacteroides* spp. are among the first groups colonising the gut^(26,51), increase further after the introduction of solid food and weaning^(32,35) and are part of the common core microbiota in adults^(3,52,53). Moreover, the ability of *Bacteroides* spp. to switch substrate specificity in response to the changing ingestion of nutrients indicates that they are adapted to the symbiotic life with human host and are permanent colonisers of the gut.

Human milk is also a source of bacteria to the infant. The predominant bacteria observed in human milk samples are Bacilli, such as *Streptococcus* spp. and *Staphylococcus* spp.^(54,55). In addition, *Bifidobacterium* spp. are present and Bacteroidetes and specific Clostridia such as butyrate-producing bacteria *Faecalibacterium* and *Roseburia* spp. have been detected^(54,56,57). The bacterial composition of breast milk varies depending on the genetic background, maternal dietary habits and demographic differences between the mothers. For example, European mothers commonly harbour *Lactobacillus* and *Bifidobacterium* spp. in their breast milk, whereas these bacteria were rarely detected in mothers from the USA, possibly as a result of technical differences and drawbacks in DNA extraction^(55,56,58). Furthermore, the mode of delivery has been shown to affect the milk microbiota composition⁽⁵⁹⁾. Milk samples from mothers who delivered their infants vaginally contained more *Leuconostocaceae* and less *Carnobacteriaceae* than milk samples from mothers who had gone through an elective caesarean section.

Maternal health status seems to have a major effect on the milk microbiota composition. For example, milk microbiota of overweight mothers differs from that of normal weight mothers^(59,60). The bacterial composition of breast milk seems to be stable at intra-individual level over time, while representing a great inter-individual variation. This suggests that human milk microbiota is highly personalised, in a manner similar to intestinal microbiota^(61–63).

Recently, the existence of a 'core' milk microbiota has been suggested⁽⁵⁴⁾. The milk core microbiota consisted of nine operational taxonomic units, corresponding to *Staphylococcus*, *Streptococcus* (Firmicutes), *Corynebacterium*, *Propionibacterium* (Actinobacteria) and *Serratia*, *Pseudomonas*, *Ralstonia*, *Sphingomonas* and *Bradyrhizobiaceae* (Proteobacteria), constituting approximately half the total bacterial community. It is noteworthy that many of the core microbiota genera are typically found from the skin and it seems likely that some part of the breast milk microbiota originates from the skin. Another origin of bacteria in human milk may be the intestinal tract of the mother. It has been suggested that intestinal bacteria could transfer within the phagocytosing cells from the gut to human milk via entero-mammary circulation of immune cells⁽⁶⁴⁾. Interestingly, *Bifidobacterium breve* is one of the most commonly detected Bifidobacterial species in human milk samples^(57,65–69) and it produces exopolysaccharide, which masks other surface antigens and presents an ability to remain immunologically 'silent'⁽⁷⁰⁾. The production of exopolysaccharide seems to be important for the persistence of *B. breve* in the gut⁽⁷⁰⁾. Speculatively, exopolysaccharide may also play a role in the survival of this bacterium within immune cells, enabling its transfer via the entero-mammary circulation route. Moreover, *B. breve* and other Bifidobacteria are known to produce specific pili that are assumed to play a role in colonisation⁽⁷¹⁾. While the origin of bacteria in human milk remains an open question, human milk bacteria should be considered as an important source of bacteria in the

establishment of intestinal microbiota during early life (Fig. 1).

Perturbations in the development of microbiota diversity and composition

Antibiotic treatments

The administration of antibiotics has been considered the most remarkable extrinsic factor affecting the microbiota composition and development during early infancy and childhood (Fig. 1). The majority of antibiotics used to treat early-life infections have a rather broad-spectrum antimicrobial activity, inhibiting the growth of both pathogenic bacteria and the beneficial members of commensal microbiota. Especially in children, the major effect is the reduction of bacteria considered to have health-promoting properties such as *Bifidobacterium* spp. and *Lactobacillus* spp., which may have long-term effects on the infants' health later in life.

After the antibiotic treatment, the overall microbiota diversity is generally decreased and the microbiota composition is often characterised by a dominance of a few bacterial groups^(72,73). In a recent study, the effect of early-life antibiotic treatment (ampicillin and gentamicin) on microbiota composition of newborn infants was analysed using a high-throughput sequencing⁽⁷²⁾. The authors reported higher proportions of Proteobacteria and reduced abundances of genera *Bifidobacterium* and *Lactobacillus* in antibiotic-treated infants when compared with untreated controls 1 month after the cessation of treatment⁽⁷²⁾. These findings are in line with previous observations considering the microbiota deviations after the administration of different types of antibiotics^(29,74). Moreover, a declined prevalence of Bacteroidetes and higher abundances of enterobacteria and enterococci have been reported in antibiotic-treated infants when compared with healthy controls^(29,72,75). In addition, a decreased abundance of Bifidobacteria have been reported in patients who have received antibiotics^(76,77). However, the sensitivity for antibiotics seems to be a strain-specific feature and thus different *Bifidobacterium* species may be distinctly affected. In a study by Mangin *et al.*⁽⁷⁸⁾, the total number of Bifidobacteria was not decreased after amoxicillin treatment for 7 d. Instead, the diversity of *Bifidobacterium* spp. population and a shift in species composition was observed. Specifically, a complete loss of *Bifidobacterium adolescentis* group and a decreased amount of *B. bifidum* were detected, whereas *B. longum* and *B. catenulatum* group bacteria were not affected⁽⁷⁸⁾. Thus, high diversity of Bifidobacterial species may protect the infant from more extensive effects of specific antibiotics.

The microbiota recovery begins shortly after the cessation of antibiotic administration but it seems to be rather slow and gradual process and the recovery remains often incomplete^(73,79,80). In a recent study, the elevated amounts of Proteobacteria could still be detected 2 months after the termination of antibiotic medication, whereas Bifidobacteria and Lactobacilli abundances were more or less recovered⁽⁷²⁾. The overgrowth of

Proteobacteria, especially *Enterobacteriaceae* after the antibiotic treatment(s) has been widely reported. This effect can be explained by the competitive advantage obtained by the production of β -lactamases. These enzymes degrade the β -lactam antibiotic structure, thus providing resistance against several antibiotics such as amoxicillin, ampicillin and gentamicin.

Interestingly, early-life antibiotic treatment(s) have been associated with the increased risk for health problems later in life such as the risk for coeliac disease (CD) development⁽⁸¹⁾, allergic diseases⁽⁸²⁾ and the increased risk of obesity at school age⁽⁸³⁾. Furthermore, prenatal exposure to antibiotics may have long-term effects on the health later in life, since maternal antibiotic use during pregnancy has been associated with an increased risk of cow's milk allergy, asthma, eczema and hay fever in their infants^(84,85). However, only a limited number of studies utilising high-throughput analysis methods on the evaluation of microbiota diversity and composition after antibiotic therapies have been published. Further studies are required to assess the impact of antibiotics on host-microbe cross-talk and interactions. Furthermore, the long-term effects of antibiotics on both microbiota and on later health status of the paediatric patients need to be urgently assessed.

Colic

Colic crying is one of the most common problems in early life confronting ~10–25% of otherwise healthy infants within the first months of life^(86,87). Colic cry is characterised by inexplicable, excessive crying >3 h/d for 3 d or more in 1 week, whereas it does not respond to any interventions such as feeding, diaper change or other solicitude procedures⁽⁸⁸⁾. Usually colic crying starts from 2-week-old to 3-month-old infants and declines after a few months. Although its aetiology and pathogenesis remain obscure, an association between colic cry and immaturity of intestinal function and/or neurodevelopmental maturity as well as excessive colonic gas production has been suggested^(89,90). In addition, an aberrant microbiota composition has been suggested to promote colicky symptoms. Microbiota diversity and stability have been observed to be lower in infants suffering from colic than in healthy control subjects^(28,90).

The most consistent finding is the decreased amounts of *Bifidobacterium* spp. and *Lactobacillus* spp. in infants with colic or extensive crying^(28,91). Conversely, elevated numbers of these bacteria have been linked to decreased colicky symptoms⁽⁹²⁾. A recent study reported an association between delayed colonisation by *Bifidobacterium infantis* and increased risk of irritability in preterm infants⁽⁸⁶⁾. Previously, the colonisation of *B. infantis* has been associated with normal development of immune tolerance and the species has been shown to be capable of normalising the permeability of intestinal mucosa⁽⁹³⁾. This effect is most likely mediated by bioactive factors secreted by *B. infantis*, which have been shown to induce the expression of tight junction proteins, thus tightening the connections between enterocytes⁽⁹⁴⁾.

Moreover, Bifidobacteria have been associated with reduced abdominal pain and discomfort in adults⁽⁹⁵⁾.

Bacteria that are increased in infants with excessive crying and colic symptoms include anaerobic Gram-negative and coliform bacteria^(28,89,90,96). It has been speculated that coliform bacteria such as *E. coli* may overtake the beneficial bacteria in colicky infants resulting in reduced induction of regulatory T cells by beneficial commensals and increased production of cytokines by antigen-presenting cells, thus leading to immune dysregulation and increased permeability of intestinal epithelium⁽⁸⁹⁾. A recent study utilising high-throughput microarray analysis reported a negative association between crying and butyrate-producing bacteria such as *Butyrivibrio crossotus*, *Eubacterium rectale* and *Eubacterium hallii*, which were found to be 1.5-fold more abundant in healthy infants without colic symptoms⁽²⁸⁾. Butyrate-producing bacteria have been shown to reduce the pain sensation⁽⁹⁷⁾ and proposed to reinforce gut defense barrier by increasing the production of mucins⁽⁹⁸⁾. Butyrate also up-regulates the expression of tight junction proteins, thus leading to decreased intestinal permeability^(99,100).

The role of aberrant microbiota composition in colic is supported by the observation that colicky symptoms could be alleviated by probiotic supplementation of *Lactobacillus reuteri* DSM 17938⁽¹⁰¹⁾. The authors suggested the improvement of gut motility and function and the reduction of visceral pain as possible mechanisms of probiotic action. Interestingly, the probiotic strain *L. reuteri* DSM 17938 has also been shown to reduce gastric distension and accelerate gastric emptying rate, which could potentially alleviate colic symptoms⁽¹⁰²⁾. Furthermore, two *L. reuteri* strains have been shown to inhibit the growth of colic-associated coliforms *in vitro*⁽⁹⁶⁾. This inhibition was mediated by bacteriocins and other inhibitory molecules produced by *L. reuteri*. Moreover, the potential of *Lactobacillus rhamnosus* GG in alleviation of colic symptoms have been reported^(86,103). In contrast, a recent study has shown that *L. reuteri* strain DSM 17938 was not effective in protecting newborns from colic⁽¹⁰⁴⁾. Thus, these studies warrant further assessment and well-planned intervention studies to characterise the potential effects of other probiotic strains in addition to *L. reuteri* and *L. rhamnosus* GG.

Atopic diseases

Atopic diseases are chronic and relapsing disorders usually starting in early childhood. Atopy has been characterised as a genetic disposition to develop an allergic reaction and produce elevated levels of IgE upon exposure to an environmental antigen⁽¹⁰⁵⁾. Atopic diseases include eczema (atopic dermatitis), allergic rhinitis (hay fever), allergic conjunctivitis and allergic asthma. In early life, the most common form of atopic disease is eczema, its prevalence being ~15–30% depending on the country studied⁽¹⁰⁶⁾. The incidences of eczema and other allergic diseases are more common in industrialised countries, the highest prevalence typically found in

Northern Europe⁽¹⁰⁵⁾. During the past decades, associations between the composition of intestinal microbiota and atopic diseases have been studied intensively.

Some of the studies evaluating the associations between microbiota composition and atopy have also addressed the microbiota composition preceding the development of disease. Reduced diversity at early life (i.e. at ages 1 week, 1 month or 4 months) has been associated with an increased risk of developing atopy or allergic disease^(107–112). However, after age 1 year the total microbiota diversity in children either developing or having eczema is comparable or even higher than that of healthy children^(36,107). In addition, the pathogenesis of atopic diseases is associated with an impaired gut barrier function and increased intestinal permeability and gastrointestinal symptoms are common among the patients⁽¹¹³⁾. Thus, it seems that sufficient diversity of microbiota in early infancy is essential for modulation of the expression of genes involved in the normal pattern of intestinal development such as postnatal intestinal maturation and maintenance of mucosal barrier^(114,115). However, microbiota development and diversification should not happen too expeditiously, since prematurely occurring changes towards an adult-type microbiota may predispose infants, e.g. with eczema⁽³⁶⁾. It is possible that an infant-type microbiota supports an adequate gut barrier function and tolerance against allergens in an immature gut and affects the maturation of the gut epithelium and immune functions in a way that results in reinforcement of the normal mucosal barrier function^(113,116).

The results on specific bacteria either increasing or decreasing the risk of developing atopic diseases or associated with their onset are still conflicting^(36,51,117–121). Aberrations in Bifidobacterial community have been associated with children with atopic diseases, most often characterised by either reduced total abundance or shifts in species community^(116,117,119,120). Furthermore, decreased amounts of *Bacteroides* spp. and increased amounts of specific Firmicutes such as *Staphylococcus aureus* and different clostridial groups, have been associated with the development and onset of allergic diseases^(36,107,122–125). Interestingly, both *Bifidobacterium* spp. and *Bacteroides* spp. have been reported to have anti-inflammatory properties via their ability to direct the cellular and physical maturation of the developing immune system^(126,127). For example, polysaccharide A from *B. fragilis* is able to direct the development of CD4+ T cells, thus inducing the differentiation of T helper (Th) 1 lineage and correction of the Th1/Th2 imbalance⁽¹²⁸⁾. Furthermore, this polysaccharide has been shown to promote immunologic tolerance through induction of regulatory T cells, resulting in suppression of IL-17 responses⁽¹²⁹⁾. Moreover, both *Bifidobacterium* and *Bacteroides* spp. have high frequency of immunostimulatory CpG motifs in their genomes, thus being rich in TLR9 ligands⁽¹⁶⁾. TLR9 stimulation is known to both enhance epithelial integrity and direct immune responses towards Th1 type (reviewed in Kant *et al.*⁽¹⁶⁾). These effects may be diminished in allergic subjects, who have reduced numbers of *Bifidobacterium* and *Bacteroides* spp.

In recent studies, increased levels of IL-17 have been associated with asthma^(130,131). Furthermore, one of the most important defence mechanisms in the epithelial barrier is IgA, which is present at high concentrations in the intestinal mucus layer⁽¹³²⁾. Low levels of IgA predisposes infants to increased binding of antigens to mucosal membrane, to increased mucosal leakiness and an increased uptake of dietary antigens⁽¹³³⁾. Low levels of IgA have also been associated with increased risk for the development of IgE-mediated allergic diseases in children⁽¹³⁴⁾. Furthermore, it has been suggested that high numbers of *Clostridium* spp. may be associated with degradation of antigen-specific IgA, which could debilitate the immature gut barrier⁽⁸⁶⁾. The protective role of specific bacteria and their compounds against atopy and allergic diseases is further supported by several clinical studies reporting the effects of probiotic strains on the alleviation of allergic symptoms even when the probiotics failed to modify the microbiota composition or diversity^(135,136). These effects can be related to the probiotic effects on the hosts' immunological functions such as improvement of the barrier function and increasing allergen-specific IgA levels, which are essential for the development of tolerance and can be considered as a marker for immune maturation^(113,134,135,137–139). Furthermore, probiotics have been suggested to have immunomodulatory impacts that affect the Th1/Th2 balance such as stimulation of Th1-type immune responses, induction of apoptosis of Th2 cells and induction of regulatory T and dendritic cells^(16,138,140–144).

Coeliac disease

CD is an autoimmune disorder of the small intestine that occurs in genetically predisposed individuals. It is caused by a reaction to dietary gluten and related prolamines, which are proteins found in maize such as wheat, barley and rye. Upon exposure to gluten, inflammatory cascade is induced in the small intestinal epithelium leading to a villous atrophy and crypt hyperplasia⁽¹⁴⁵⁾. Typical symptoms include different gastrointestinal symptoms such as diarrhoea, abdominal pain and distension⁽¹⁴⁶⁾. Untreated CD may lead to weight loss, malabsorption and growth disturbances in paediatric patients⁽¹⁴⁶⁾. The CD is a multifactorial disorder and its pathogenesis involves both genetic and environmental factors. For example, a high frequency of infectious episodes early in life^(147,148), antibiotic treatments⁽⁸¹⁾ as well as the timing of gluten introduction into the diet^(149,150) have been associated with the onset of CD in genetically susceptible infants (Fig. 1).

A specific role for the intestinal microbiota in CD development has been suggested^(149,151,152). Indeed, deviations in faecal and duodenal microbiota associated with CD have been reported^(149,151–153), although recent studies utilising high-throughput methods have reported comparable microbiota compositions in patients and healthy controls^(154–157). A recent study utilising a high-throughput microarray method in analysing duodenal biopsies of paediatric CD patients in Finland found that while the overall microbiota composition was comparable between CD and healthy subjects, a profile of

eight bacterial groups was observed to distinguish patients from healthy controls⁽¹⁵⁷⁾. This profile was characterised by higher abundances of bacteria related to *Prevotella melaninogenica*, *Haemophilus* and *Serratia* spp., whereas those related to *P. oralis*, *P. cinnamivorans*, *Ruminococcus bromii*, *Proteus* and *Clostridium stercorarium* were decreased in CD patients⁽¹⁵⁷⁾. Also the total abundance of *Prevotella* spp. was found to be slightly increased (did not reach a statistical significance)⁽¹⁵⁷⁾, which supports the previous findings by a Swedish research group, who found an association of elevated total abundance of *Prevotella* spp. and CD^(158,159). Microbiota dysbiosis of CD patients may be characterised by an increased microbiota diversity^(152,153,160,161), but these findings have been contradicted recently⁽¹⁵⁷⁾. Furthermore, patients with active CD seem to have an increased inter-individual similarity when compared with patients in remission state or healthy controls^(153,158). It has been suggested that altered glycosylation patterns observed in mucosa of CD patients⁽¹⁵⁸⁾ may create a more selective pressure leading to a more homogenous microbial colonisation⁽¹⁵³⁾.

Such microbiota deviations are only partly restored after long-term treatment with gluten-free diet. A higher diversity and a complete rearrangement in *Eubacterium* species community as well as changed metabolomic profiles were observed in CD patients who had followed gluten-free diet for 2 years when compared to healthy controls⁽¹⁶²⁾. In contrast, the proportions of *E. coli* and *Staphylococcus* were observed to normalise after treatment with gluten-free diet⁽¹⁶³⁾.

In the active phase of CD, the reduction of Gram-positive bacteria population, especially the numbers or proportion of *Bifidobacterium* spp. has been reported^(152,163). Such findings may be of interest, since Bifidobacteria have been suggested to alleviate gastrointestinal symptoms of adult coeliac patients⁽¹⁶⁴⁾ and have been associated with reduced abdominal pain and discomfort in healthy adults⁽⁹⁵⁾. In contrast to declined proportions of Gram-positives, Gram-negative bacteria such as *Clostridium* groups^(160,163), *Prevotella* spp.^(157,159) and *E. coli*^(153,163) seem to be increased in paediatric CD patients. The most constant finding is the higher abundance of *Bacteroides* spp. in faeces and duodenal biopsies of CD patients^(152,153,163), although a complete lack of the members of phylum Bacteroidetes was observed in CD predisposed infants in a prospective study⁽¹⁴⁹⁾.

Furthermore, another study reported a reduction in IgA-coated bacteria, especially IgA-coated *Bacteroides* in faeces of untreated and treated CD patients when compared to healthy controls⁽¹⁵¹⁾. The authors stated that host defences against this bacterial group might be reduced in coeliac disease, thus allowing its increased colonisation. Moreover, shifts in *Bacteroides* spp. composition in early-life microbiota have been reported in infants with high genetic risk for CD development compared to infants with low genetic risk⁽¹⁶³⁾. In detail, *Bacteroides uniformis*, *B. ovatus* and *B. plebeius* were associated with a low genetic risk, whereas *B. vulgatus* seems to be more prevalent both in high-risk infants⁽¹⁶⁵⁾.

and in infants with active CD⁽¹⁵³⁾. Furthermore, *B. fragilis* has been associated with an increased risk for CD development in genetically predisposed infants who were formula-fed⁽¹⁶⁶⁾. Interestingly, polysaccharide A produced by *B. fragilis* has been shown to induce the differentiation of Th1-type immune cells⁽¹²⁸⁾. In addition, a decreased duodenal expression of TLR2 and increased expression of TLR9 and IL-8 have been observed in infants with CD⁽¹⁵⁵⁾. It has been suggested that increased TLR9 signalling in the duodenum may contribute to the Th1 response found in the small intestinal mucosa of CD subjects^(155,157). Furthermore, the expression of tight junction protein coding ZO-1 is significantly down-regulated in untreated CD patients when compared to patients with treated CD⁽¹⁵⁷⁾. Thus, a synergistic effect of *Bacteroides* spp. and increased TLR9 signalling may lead to an excessive induction of Th1-type immune response, which may contribute to the onset and/or remission of the coeliac disease. Collectively, it seems that both altered microbiota composition and dysregulated host–microbe interaction may have a role in CD.

Conclusions

The microbiota development is a gradual process, which begins during early phases of pregnancy. During the succession of microbes some bacterial groups reach the degree of maturation earlier than others. The development of the intestinal microbiota is likely to continue throughout childhood and adolescence and may not be completed until the human host reaches adulthood. The course of development is affected by both life-style factors and medical practices that direct the intestinal colonisation and have an impact on health later in life. Our understanding of both the compositional development and the diversity and function of the intestinal microbiota and its effects on health and disease is constantly improving but further studies are still needed to address the long-term influence of early-life gut microbiota on intestinal, systemic immunity and other organ systems.

Acknowledgements

None.

Financial Support

This work was supported by The Finnish Graduate School on Applied Bioscience: Bioengineering, Food and Nutrition, Environment (for L. N.), The Academy of Finland (Grant no. 258438 for R. S. and Grant numbers 137389 and 141140 for W. de V.) and the ERC Advanced Grant no. 250172 (Microbes Inside) of the European Research Council.

Conflicts of Interest

None.

Authorship

L. N. wrote the paper; R. S. designed Fig. 1; all authors corrected and approved the manuscript.

References

1. Zoetendal EG, Rajilić-Stojanović M & de Vos WM (2008) High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. *Gut* **57**, 1605–1615.
2. Scholtens PA, Oozeer R, Martin R *et al.* (2012) The early settlers: intestinal microbiology in early life. *Annu Rev Food Sci Technol* **3**, 425–447.
3. Qin J & Members of MetaHIT Consortium (2010) A human gut microbial gene catalog established by deep metagenomic sequencing. *Nature* **464**, 59–65.
4. Rajilić-Stojanović M, Heilig HG, Tims S *et al.* (2012) Long-term monitoring of the human intestinal microbiota composition. *Environ Microbiol* **15**, 1146–1159.
5. Rajilić-Stojanović M (2013) Function of the microbiota. *Best Pract Res Clin Gastroenterol* **27**, 5–16.
6. Rook GA, Raison CL & Lowry CA (2014) Microbial “Old Friends”, immunoregulation and socio-economic status. *Clin Exp Immunol* (In the Press).
7. Pararas MV, Skevaki CL & Kafetzis DA (2006) Preterm birth due to maternal infection: causative pathogens and modes of prevention. *Eur J Clin Microbiol Infect Dis* **25**, 562–569.
8. Wang X, Buhimschi CS, Temoin S *et al.* (2013) Comparative microbial analysis of paired amniotic fluid and cord blood from pregnancies complicated by preterm birth and early-onset neonatal sepsis. *PLoS ONE* **8**, e56131.
9. DiGiulio DB, Romero R, Amogan HP *et al.* (2008) Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. *PLoS ONE* **3**, e3056.
10. DiGiulio DB, Romero R, Kusanovic JP *et al.* (2010) Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. *Am J Reprod Immunol* **64**, 38–57.
11. Satokari R, Grönroos T, Laitinen K *et al.* (2009) *Bifidobacterium* and *Lactobacillus* DNA in the human placenta. *Lett Appl Microbiol* **48**, 8–12.
12. Rautava S, Collado MC, Salminen S *et al.* (2012) Probiotics modulate host-microbe interaction in the placenta and fetal gut: a randomized, double-blind, placebo-controlled trial. *Neonatology* **102**, 178–184.
13. Goldenberg RL, Culhane JF, Iams JD *et al.* (2008) Epidemiology and causes of preterm birth. *Lancet* **371**, 75–84.
14. Nanthakumar N, Meng D, Goldstein AM *et al.* (2011) The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. *PLoS ONE* **6**, e17776.
15. Gribar SC, Sodhi CP, Richardson WM *et al.* (2009) Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. *J Immunol* **182**, 636–646.
16. Kant R, de Vos WM, Palva A *et al.* (2013) Immunostimulatory CpG motifs in the genomes of gut bacteria and their role in human health and disease. *J Med Microbiol* **63**, 293–308.



17. Downard CD, Renaud E, St Peter SD *et al.* (2012) Treatment of necrotizing enterocolitis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. *J Pediatr Surg* **47**, 2111–2122.
18. Rachmilewitz D, Katakura K, Karmeli F *et al.* (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. *Gastroenterology* **126**, 520–528.
19. Kumagai M, Kimura A, Takei H *et al.* (2007) Perinatal bile acid metabolism: bile acid analysis of meconium of preterm and full-term infants. *J Gastroenterol* **42**, 904–910.
20. Moles L, Gomez M, Heilig H *et al.* (2013) Bacterial diversity in meconium of preterm neonates and evolution of their fecal microbiota during the first month of life. *PLoS ONE* **8**, e66986.
21. Dominguez-Bello MG, Costello EK, Contreras M *et al.* (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci USA* **107**, 11971–11975.
22. Jimenez E, Marin ML, Martin R *et al.* (2008) Is meconium from healthy newborns actually sterile? *Res Microbiol* **159**, 187–193.
23. Gosalbes MJ, Llop S, Valles Y *et al.* (2013) Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated with maternal eczema and respiratory problems in infants. *Clin Exp Allergy* **43**, 198–211.
24. Hu J, Nomura Y, Bashir A *et al.* (2013) Diversified microbiota of meconium is affected by maternal diabetes status. *PLoS ONE* **8**, e78257.
25. Adlerberth I & Wold AE (2009) Establishment of the gut microbiota in Western infants. *Acta Paediatr* **98**, 229–238.
26. Palmer C, Bik EM, Digiulio DB *et al.* (2007) Development of the human infant intestinal microbiota. *PLoS ONE* **5**, e177.
27. Avershina E, Storro O, Oien T *et al.* (2013) Major faecal microbiota shifts in composition and diversity with age in a geographically restricted cohort of mothers and their children. *FEMS Microbiol Ecol* **87**, 280–290.
28. de Weerth C, Fuentes S, Puylaert P *et al.* (2013) Intestinal microbiota of infants with colic: development and specific signatures. *Pediatrics* **131**, e550–e558.
29. Fallani M, Young D, Scott J *et al.* (2010) Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics. *J Pediatr Gastroenterol Nutr* **51**, 77–84.
30. Turroni F, Peano C, Pass DA *et al.* (2012) Diversity of bifidobacteria within the infant gut microbiota. *PLoS ONE* **7**, e36957.
31. Bezirtzoglou E & Stavropoulou E (2011) Immunology and probiotic impact of the newborn and young children intestinal microflora. *Anaerobe* **17**, 369–374.
32. Roger LC & McCartney AL (2010) Longitudinal investigation of the faecal microbiota of healthy full-term infants using fluorescence *in situ* hybridization and denaturing gradient gel electrophoresis. *Microbiology* **156**, 3317–3328.
33. Fallani M, Amari S, Uusijärvi A *et al.* (2011) Determinants of the human infant intestinal microbiota after the introduction of first complementary foods in infant samples from five European centres. *Microbiology* **157**, 1385–1392.
34. Fan W, Huo G, Li X *et al.* (2013) Impact of diet in shaping gut microbiota revealed by a comparative study in infants during the six months of life. *J Microbiol Biotechnol* **24**, 133–143.
35. Koenig JE, Spor A, Scalfone N *et al.* (2011) Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci USA* **108**, S4578–S4585.
36. Nylund L, Satokari R, Nikkilä J *et al.* (2013) Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. *BMC Microbiol* **13**, 12.
37. Ringel-Kulka T, Cheng J, Ringel Y *et al.* (2013) Intestinal microbiota in healthy U.S. young children and adults – a high throughput microarray analysis. *PLoS ONE* **8**, e64315.
38. Avershina E, Storro O, Oien T *et al.* (2013) Bifidobacterial succession and correlation networks in a large unselected cohort of mothers and their children. *Appl Environ Microbiol* **79**, 497–507.
39. Mackie RI, Sghir A & Gaskins HR (1999) Developmental microbial ecology of the neonatal gastrointestinal tract. *Am J Clin Nutr* **69**, 1035S–1045S.
40. Agans R, Rigsbee L, Kenche H *et al.* (2011) Distal gut microbiota of adolescent children is different from that of adults. *FEMS Microbiol Ecol* **77**, 404–412.
41. Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. *Glycobiology* **22**, 1147–1162.
42. Thurl S, Munzert M, Henker J *et al.* (2010) Variation of human milk oligosaccharides in relation to milk groups and lactational periods. *Br J Nutr* **104**, 1261–1271.
43. Albrecht S, Schols HA, van den Heuvel EG *et al.* (2011) Occurrence of oligosaccharides in feces of breast-fed babies in their first six months of life and the corresponding breast milk. *Carbohydr Res* **346**, 2540–2550.
44. Zivkovic AM, German JB, Lebrilla CB *et al.* (2011) Human milk glyco-biome and its impact on the infant gastrointestinal microbiota. *Proc Natl Acad Sci USA* **108**, S4653–S4658.
45. Marcobal A & Sonnenburg JL (2012) Human milk oligosaccharide consumption by intestinal microbiota. *Clin Microbiol Infect* **18**, Suppl. 4, 12–15.
46. Sela DA, Garrido D, Lerno L *et al.* (2012) *Bifidobacterium longum* subsp. *infantis* ATCC 15697 alpha-fucosidases are active on fucosylated human milk oligosaccharides. *Appl Environ Microbiol* **78**, 795–803.
47. Sela DA, Chapman J, Adeuya A *et al.* (2008) The genome sequence of *Bifidobacterium longum* subsp. *infantis* reveals adaptations for milk utilization within the infant microbiome. *Proc Natl Acad Sci USA* **105**, 18964–18969.
48. Gonzalez R, Klaassens ES, Malinen E *et al.* (2008) Differential transcriptional response of *Bifidobacterium longum* to human milk, formula milk, and galactooligosaccharide. *Appl Environ Microbiol* **74**, 4686–4694.
49. Martens EC, Lowe EC, Chiang H *et al.* (2011) Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. *PLoS Biol* **9**, e1001221.
50. Tannock GW, Lawley B, Munro K *et al.* (2013) Comparison of the compositions of the stool microbiotas of infants fed goat milk formula, cow milk-based formula, or breast milk. *Appl Environ Microbiol* **79**, 3040–3048.
51. Penders J, Stobberingh E, Thijs C *et al.* (2006) Molecular fingerprinting of the intestinal microbiota of infants in whom atopic eczema was or was not developing. *Clin Exp Allergy* **36**, 1602–1608.
52. Rajilić-Stojanović M, Heilig H, Molenaar D *et al.* (2009) Development and application of The Human Intestinal Tract Chip (HITChip), a phylogenetic microarray: absence of universally conserved phylotypes in the abundant microbiota of young and elderly adults. *Environ Microbiol* **11**, 1736–1743.

53. Huse SM, Ye Y, Zhou Y *et al.* (2012) A core human microbiome as viewed through 16S rRNA sequence clusters. *PLoS ONE* **7**, e34242.
54. Hunt KM, Foster JA, Forney LJ *et al.* (2011) Characterization of the diversity and temporal stability of bacterial communities in human milk. *PLoS ONE* **6**, e21313.
55. Jost T, Lacroix C, Braegger CP *et al.* (2013) Vertical mother-neonate transfer of maternal gut bacteria via breastfeeding. *Environ Microbiol* (In the Press).
56. Jost T, Lacroix C, Braegger C *et al.* (2013) Assessment of bacterial diversity in breast milk using culture-dependent and culture-independent approaches. *Br J Nutr* **110**, 1253–1262.
57. Martin R, Jimenez E, Heilig H *et al.* (2009) Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis and quantitative real-time PCR. *Appl Environ Microbiol* **75**, 965–969.
58. Ward TL, Hosid S, Ioshikhes I *et al.* (2013) Human milk metagenome: a functional capacity analysis. *BMC Microbiol* **13**, 116.
59. Cabrera-Rubio R, Collado MC, Laitinen K *et al.* (2012) The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. *Am J Clin Nutr* **96**, 544–551.
60. Collado MC, Laitinen K, Salminen S *et al.* (2012) Maternal weight and excessive weight gain during pregnancy modify the immunomodulatory potential of breast milk. *Pediatr Res* **72**, 77–85.
61. Costello EK, Lauber CL, Hamady M *et al.* (2009) Bacterial community variation in human body habitats across space and time. *Science* **326**, 1694–1697.
62. Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. *Nature* **486**, 207–214.
63. Ursell LK, Clemente JC, Rideout JR *et al.* (2012) The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. *J Allergy Clin Immunol* **129**, 1204–1208.
64. Grönlund MM, Gueimonde M, Laitinen K *et al.* (2007) Maternal breast-milk and intestinal bifidobacteria guide the compositional development of the *Bifidobacterium* microbiota in infants at risk of allergic disease. *Clin Exp Allergy* **37**, 1764–1772.
65. Boesten R, Schuren F, Ben Amor K *et al.* (2011) *Bifidobacterium* population analysis in the infant gut by direct mapping of genomic hybridization patterns: potential for monitoring temporal development and effects of dietary regimens. *Microb Biotechnol* **4**, 417–427.
66. Alp G, Aslim B, Suludere Z *et al.* (2010) The role of hemagglutination and effect of exopolysaccharide production on bifidobacteria adhesion to Caco-2 cells *in vitro*. *Microbiol Immunol* **54**, 658–665.
67. Turrone F, Foroni E, Serafini F *et al.* (2011) Ability of *Bifidobacterium breve* to grow on different types of milk: exploring the metabolism of milk through genome analysis. *Appl Environ Microbiol* **77**, 7408–7417.
68. Roger LC, Costabile A, Holland DT *et al.* (2010) Examination of faecal *Bifidobacterium* populations in breast- and formula-fed infants during the first 18 months of life. *Microbiology* **156**, 3329–3341.
69. Solis G, de Los Reyes-Gavilan CG, Fernandez N *et al.* (2010) Establishment and development of lactic acid bacteria and bifidobacteria microbiota in breast-milk and the infant gut. *Anaerobe* **16**, 307–310.
70. Fanning S, Hall LJ, Cronin M *et al.* (2012) Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. *Proc Natl Acad Sci USA* **109**, 2108–2113.
71. O'Connell Motherway M, Zomer A, Leahy SC *et al.* (2011) Functional genome analysis of *Bifidobacterium breve* UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. *Proc Natl Acad Sci USA* **108**, 11217–11222.
72. Fouhy F, Guinane CM, Hussey S *et al.* (2012) High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. *Antimicrob Agents Chemother* **56**, 5811–5820.
73. Dethlefsen L & Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci USA* **108**, S4554–S4561.
74. Rea MC, Dobson A, O'Sullivan O *et al.* (2011) Effect of broad- and narrow-spectrum antimicrobials on *Clostridium difficile* and microbial diversity in a model of the distal colon. *Proc Natl Acad Sci USA* **108**, S4639–S4644.
75. Tanaka S, Kobayashi T, Songjinda P *et al.* (2009) Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. *FEMS Immunol Med Microbiol* **56**, 80–87.
76. Hussey S, Wall R, Gruffman E *et al.* (2011) Parenteral antibiotics reduce bifidobacteria colonization and diversity in neonates. *Int J Microbiol* doi: 10.1155/2011/130574.
77. Mangin I, Leveque C, Magne F *et al.* (2012) Long-term changes in human colonic *Bifidobacterium* populations induced by a 5-day oral amoxicillin-clavulanic acid treatment. *PLoS ONE* **7**, e50257.
78. Mangin I, Suau A, Gotteland M *et al.* (2010) Amoxicillin treatment modifies the composition of *Bifidobacterium* species in infant intestinal microbiota. *Anaerobe* **16**, 433–438.
79. Jernberg C, Lofmark S, Edlund C *et al.* (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. *Microbiology* **156**, 3216–3223.
80. Jakobsson HE, Jernberg C, Andersson AF *et al.* (2010) Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. *PLoS ONE* **5**, e9836.
81. Mårild K, Ye W, Leibold B *et al.* (2013) Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. *BMC Gastroenterol* **13**, 109.
82. Foliaki S, Pearce N, Björkstén B *et al.* (2009) Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis, and eczema in children 6 and 7 years old: International Study of Asthma and Allergies in Childhood Phase III. *J Allergy Clin Immunol* **124**, 982–989.
83. Ajslev TA, Andersen CS, Gamborg M *et al.* (2011) Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. *Int J Obes (Lond)* **35**, 522–529.
84. McKeever TM, Lewis SA, Smith C *et al.* (2002) The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database. *Am J Respir Crit Care Med* **166**, 827–832.
85. Metsälä J, Lundqvist A, Virta LJ *et al.* (2013) Mother's and offspring's use of antibiotics and infant allergy to cow's milk. *Epidemiology* **24**, 303–309.

86. Pärtty A, Luoto R, Kalliomäki M *et al.* (2013) Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. *J Pediatr* **163**, 1272–1277. e1–2.
87. Milidou I, Sondergaard C, Jensen MS *et al.* (2013) Gestational age, small for gestational age, and infantile colic. *Paediatr Perinat Epidemiol* **28**, 138–145.
88. Wessel MA, Cobb JC, Jackson EB *et al.* (1954) Paroxysmal fussing in infancy, sometimes called colic. *Pediatrics* **14**, 421–435.
89. Savino F, Cordisco L, Tarasco V *et al.* (2009) Molecular identification of coliform bacteria from colicky breastfed infants. *Acta Paediatr* **98**, 1582–1588.
90. Rhoads JM, Fatheree NY, Norori J *et al.* (2009) Altered fecal microflora and increased fecal calprotectin in infants with colic. *J Pediatr* **155**, 823–828.
91. Pärtty A, Kalliomäki M, Endo A *et al.* (2012) Compositional development of *Bifidobacterium* and *Lactobacillus* microbiota is linked with crying and fussing in early infancy. *PLoS ONE* **7**, e32495.
92. Roos S, Dicksved J, Tarasco V *et al.* (2013) 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with *Lactobacillus reuteri* DSM 17938. *PLoS ONE* **8**, e56710.
93. Chichlowski M, De Lartigue G, German JB *et al.* (2012) Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function. *J Pediatr Gastroenterol Nutr* **55**, 321–327.
94. Ewaschuk JB, Diaz H, Meddings L *et al.* (2008) Secreted bioactive factors from *Bifidobacterium infantis* enhance epithelial cell barrier function. *Am J Physiol Gastrointest Liver Physiol* **295**, G1025–G1034.
95. Jalanka-Tuovinen J, Salonen A, Nikkilä J *et al.* (2011) Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. *PLoS ONE* **6**, e23035.
96. Savino F, Cordisco L, Tarasco V *et al.* (2011) Antagonistic effect of *Lactobacillus* strains against gas-producing coliforms isolated from colicky infants. *BMC Microbiol* **11**, 157.
97. Vanhoutvin SA, Troost FJ, Kilkens TO *et al.* (2009) The effects of butyrate enemas on visceral perception in healthy volunteers. *Neurogastroenterol Motil* **21**, 952–e76.
98. Burger-van Paassen N, Vincent A, Puiman PJ *et al.* (2009) The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. *Biochem J* **420**, 211–219.
99. Ma X, Fan PX, Li LS *et al.* (2012) Butyrate promotes the recovering of intestinal wound healing through its positive effect on the tight junctions. *J Anim Sci* **90**, S266–S268.
100. Wang HB, Wang PY, Wang X *et al.* (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. *Dig Dis Sci* **57**, 3126–3135.
101. Savino F, Cordisco L, Tarasco V *et al.* (2010) *Lactobacillus reuteri* DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. *Pediatrics* **126**, e526–e533.
102. Indrio F, Riezzo G, Raimondi F *et al.* (2011) *Lactobacillus reuteri* accelerates gastric emptying and improves regurgitation in infants. *Eur J Clin Invest* **41**, 417–422.
103. Pärtty A & Isolauri E (2012) Gut microbiota and infant distress – the association between compositional development of the gut microbiota and fussing and crying in early infancy. *Microb Ecol Health Dis* **23** (online publication; doi:10.3402/mehd.v23i0.18577).
104. Sung V, Hiscock H, Tang ML *et al.* (2014) Treating infant colic with the probiotic *Lactobacillus reuteri*: double blind, placebo controlled randomised trial. *Br Med J* **348**, g2107.
105. Bieber T (2010) Atopic dermatitis. *Ann Dermatol* **22**, 125–137.
106. Deckers IA, McLean S, Linssen S *et al.* (2012) Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. *PLoS ONE* **7**, e39803.
107. Abrahamsson TR, Jakobsson HE, Andersson AF *et al.* (2012) Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol* **129**, 434–440. e2.
108. Bisgaard H, Li N, Bonnelykke K *et al.* (2011) Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. *J Allergy Clin Immunol* **128**, 646–652. e1–5.
109. Forno E, Onderdonk AB, McCracken J *et al.* (2008) Diversity of the gut microbiota and eczema in early life. *Clin Mol Allergy* **6**, 11.
110. Wang M, Karlsson C, Olsson C *et al.* (2008) Reduced diversity in the early fecal microbiota of infants with atopic eczema. *J Allergy Clin Immunol* **121**, 129–134.
111. Ismail IH, Oppedisano F, Joseph SJ *et al.* (2012) Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. *Pediatr Allergy Immunol* **23**, 674–681.
112. Kalliomäki M, Kirjavainen P, Eerola E *et al.* (2001) Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. *J Allergy Clin Immunol* **107**, 129–134.
113. Rosenfeldt V, Benfeldt E, Valerius NH *et al.* (2004) Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. *J Pediatr* **145**, 612–616.
114. Sjögren YM, Tomicic S, Lundberg A *et al.* (2009) Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses. *Clin Exp Allergy* **39**, 1842–1851.
115. Hooper LV & Macpherson AJ (2010) Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol* **10**, 159–169.
116. Maynard CL, Elson CO, Hatton RD *et al.* (2012) Reciprocal interactions of the intestinal microbiota and immune system. *Nature* **489**, 231–241.
117. Sepp E, Julge K, Mikelsaar M *et al.* (2005) Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. *Clin Exp Allergy* **35**, 1141–1146.
118. Stjepetova J, Sepp E, Julge K *et al.* (2007) Molecularly assessed shifts of *Bifidobacterium* ssp. and less diverse microbial communities are characteristic of 5-year-old allergic children. *FEMS Immunol Med Microbiol* **51**, 260–269.
119. Johansson MA, Sjögren YM, Persson JO *et al.* (2011) Early colonization with a group of *Lactobacilli* decreases the risk for allergy at five years of age despite allergic heredity. *PLoS ONE* **6**, e23031.
120. Gore C, Munro K, Lay C *et al.* (2008) *Bifidobacterium pseudocatenulatum* is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. *J Allergy Clin Immunol* **121**, 135–140.
121. Mah K, Chin V, Wong W *et al.* (2007) Effect of a milk formula containing probiotics on the fecal microbiota of

- asian infants at risk of atopic diseases. *Pediatr Res* **62**, 674–679.
122. Björkstén B, Sepp E, Julge K *et al.* (2001) Allergy development and the intestinal microflora during the first year of life. *J Allergy Clin Immunol* **108**, 516–520.
 123. Sjögren YM, Jenmalm MC, Böttcher MF *et al.* (2009) Altered early infant gut microbiota in children developing allergy up to 5 years of age. *Clin Exp Allergy* **39**, 518–526.
 124. Storro O, Oien T, Langsrud O *et al.* (2011) Temporal variations in early gut microbial colonization are associated with allergen-specific immunoglobulin E but not atopic eczema at 2 years of age. *Clin Exp Allergy* **41**, 1545–1554.
 125. Thompson-Chagoyan OC, Fallani M, Maldonado J *et al.* (2011) Faecal microbiota and short-chain fatty acid levels in faeces from infants with cow's milk protein allergy. *Int Arch Allergy Immunol* **156**, 325–332.
 126. Hooper LV, Wong MH, Thelin A *et al.* (2001) Molecular analysis of commensal host-microbial relationships in the intestine. *Science* **291**, 881–884.
 127. Pagnini C, Saeed R, Bamias G *et al.* (2010) Probiotics promote gut health through stimulation of epithelial innate immunity. *Proc Natl Acad Sci USA* **107**, 454–459.
 128. Mazmanian SK, Liu CH, Zhanabos AO *et al.* (2005) An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell* **122**, 107–118.
 129. Round JL, Lee SM, Li J *et al.* (2011) The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. *Science* **332**, 974–977.
 130. Alyasin S, Karimi MH, Amin R *et al.* (2013) Interleukin-17 gene expression and serum levels in children with severe asthma. *Iran J Immunol* **10**, 177–185.
 131. Ramirez-Velazquez C, Castillo EC, Guido-Bayardo L *et al.* (2013) IL-17-producing peripheral blood CD177+ neutrophils increase in allergic asthmatic subjects. *Allergy Asthma Clin Immunol* **9**, 23.
 132. Brandtzaeg P (2009) Mucosal immunity: induction, dissemination, and effector functions. *Scand J Immunol* **70**, 505–515.
 133. Johansen FE, Pekna M, Norderhaug IN *et al.* (1999) Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. *J Exp Med* **190**, 915–922.
 134. Kukkonen K, Kuitunen M, Haahtela T *et al.* (2010) High intestinal IgA associates with reduced risk of IgE-associated allergic diseases. *Pediatr Allergy Immunol* **21**, 67–73.
 135. Nermes M, Kantele JM, Atosuo TJ *et al.* (2011) Interaction of orally administered *Lactobacillus rhamnosus* GG with skin and gut microbiota and humoral immunity in infants with atopic dermatitis. *Clin Exp Allergy* **41**, 370–377.
 136. Elazab N, Mendy A, Gasana J *et al.* (2013) Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. *Pediatrics* **132**, e666–e676.
 137. Mantis NJ, Rol N & Cortes B (2011) Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. *Mucosal Immunol* **4**, 603–611.
 138. Rautava S, Arvilommi H & Isolauri E (2006) Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. *Pediatr Res* **60**, 221–224.
 139. Di Mauro A, Neu J, Riezzo G *et al.* (2013) Gastrointestinal function development and microbiota. *Ital J Pediatr* **39**, 15.
 140. Kwon HK, Lee CG, So JS *et al.* (2010) Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. *Proc Natl Acad Sci USA* **107**, 2159–2164.
 141. Lyons A, O'Mahony D, O'Brien F *et al.* (2010) Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in murine allergy models. *Clin Exp Allergy* **40**, 811–819.
 142. Marschan E, Kuitunen M, Kukkonen K *et al.* (2008) Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. *Clin Exp Allergy* **38**, 611–618.
 143. Torii S, Torii A, Itoh K *et al.* (2011) Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum markers of atopic dermatitis in children. *Int Arch Allergy Immunol* **154**, 236–245.
 144. West CE, Hammarstrom ML & Hernell O (2009) Probiotics during weaning reduce the incidence of eczema. *Pediatr Allergy Immunol* **20**, 430–437.
 145. Green PH & Jabri B (2006) Celiac disease. *Annu Rev Med* **57**, 207–221.
 146. Murch S, Jenkins H, Auth M *et al.* (2013) Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and management of coeliac disease in children. *Arch Dis Child* **98**, 806–811.
 147. Stene LC, Honeyman MC, Hoffenberg EJ *et al.* (2006) Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. *Am J Gastroenterol* **101**, 2333–2340.
 148. Myleus A, Hernell O, Gotthofors L *et al.* (2012) Early infections are associated with increased risk for celiac disease: an incident case-referent study. *BMC Pediatr* **12**, 194.
 149. Sellitto M, Bai G, Serena G *et al.* (2012) Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. *PLoS ONE* **7**, e33387.
 150. Ivarsson A, Persson LA, Nystrom L *et al.* (2000) Epidemic of coeliac disease in Swedish children. *Acta Paediatr* **89**, 165–171.
 151. Sanz Y, De Pama G & Laparra M (2011) Unraveling the ties between celiac disease and intestinal microbiota. *Int Rev Immunol* **30**, 207–218.
 152. De Palma G, Nadal I, Medina M *et al.* (2010) Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. *BMC Microbiol* **10**, 63.
 153. Schippa S, Iebba V, Barbato M *et al.* (2010) A distinctive 'microbial signature' in celiac pediatric patients. *BMC Microbiol* **10**, 175.
 154. de Meij TG, Budding AE, Grasman ME *et al.* (2013) Composition and diversity of the duodenal mucosa-associated microbiome in children with untreated coeliac disease. *Scand J Gastroenterol* **48**, 530–536.
 155. Kalliomäki M, Satokari R, Lähteenoja H *et al.* (2012) Expression of microbiota, Toll-like receptors, and their regulators in the small intestinal mucosa in celiac disease. *J Pediatr Gastroenterol Nutr* **54**, 727–732.
 156. Nistal E, Caminero A, Herran AR *et al.* (2012) Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. *Inflamm Bowel Dis* **18**, 649–656.
 157. Cheng J, Kalliomäki M, Heilig HG *et al.* (2013) Duodenal microbiota composition and mucosal homeostasis in pediatric celiac disease. *BMC Gastroenterol* **13**, 113.



158. Forsberg G, Fahlgren A, Horstedt P *et al.* (2004) Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. *Am J Gastroenterol* **99**, 894–904.
159. Ou G, Hedberg M, Horstedt P *et al.* (2009) Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. *Am J Gastroenterol* **104**, 3058–3067.
160. Nadal I, Donat E, Ribes-Koninckx C *et al.* (2007) Imbalance in the composition of the duodenal microbiota of children with coeliac disease. *J Med Microbiol* **56**, 1669–1674.
161. Sanchez E, Donat E, Ribes-Koninckx C *et al.* (2013) Duodenal-mucosal bacteria associated with celiac disease in children. *Appl Environ Microb* **79**, 5472–5479.
162. Di Cagno R, De Angelis M, De Pasquale I *et al.* (2011) Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. *BMC Microbiol* **11**, 219.
163. Collado MC, Donat E, Ribes-Koninckx C *et al.* (2009) Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. *J Clin Pathol* **62**, 264–269.
164. Smecuol E, Hwang HJ, Sugai E *et al.* (2013) Exploratory, randomized, double-blind, placebo-controlled study on the effects of *Bifidobacterium infantis* natrene life start strain super strain in active celiac disease. *J Clin Gastroenterol* **47**, 139–147.
165. Sanchez E, De Palma G, Capilla A *et al.* (2011) Influence of environmental and genetic factors linked to celiac disease risk on infant gut colonization by *Bacteroides* species. *Appl Environ Microbiol* **77**, 5316–5323.
166. Palma GD, Capilla A, Nova E *et al.* (2012) Influence of milk-feeding type and genetic risk of developing coeliac disease on intestinal microbiota of infants: the PROFICEL study. *PLoS ONE* **7**, e30791.